GlassScriptPhysician profile
Waddah Salman
NPI 1568441012
$6,066.31
in general payments reported to CMS, 2019-2025
32 companies · $327 in 2025
The $327 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $677 · 2020: $811 · 2021: $901 · 2022: $1,758 · 2023: $740 · 2024: $852 · 2025: $327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,919.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,918.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,021.00 | 2019-2025 | Repatha, Repatha |
| Bard Peripheral Vascular, INC. | $874.22 | 2022-2024 | Venclose Maven Catheter |
| Novartis Pharmaceuticals Corporation | $859.94 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $409.57 | 2019-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $313.58 | 2021-2024 | Verquvo |
| Janssen Pharmaceuticals, INC | $306.84 | 2019-2022 | |
| Astellas Pharma US INC | $233.26 | 2020 | |
| Pfizer INC. | $190.46 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.63 | 2019-2023 | Jardiance |
| Amarin Pharma, INC. | $182.16 | 2019-2021 | |
| Cvrx, INC. | $164.77 | 2021-2025 | Barostim Neo System |
| Bayer Healthcare Pharmaceuticals INC. | $154.90 | 2021-2024 | |
| Philips North America LLC | $152.19 | 2020-2024 | (Ck4) Mcot, (Ck7) Extended Holter |
| Impulse Dynamics (USA) INC. | $123.68 | 2022-2023 | Optimizer |
| Abbott Laboratories | $105.66 | 2024-2025 | Cardiomems |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $101.72 | 2019-2021 | |
| Boston Scientific Corporation | $94.41 | 2022-2023 | Varithena Administration Pack |
| Astrazeneca Pharmaceuticals LP | $74.75 | 2020-2023 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $71.71 | 2021-2025 | Camzyos |
| Shockwave Medical, INC | $63.03 | 2022 | |
| Abiomed | $58.31 | 2023 | Impella |
| Inspire Medical Systems, INC. | $55.15 | 2023-2024 | Inspire |
| Bardy Diagnostics, INC. | $52.00 | 2019-2021 | |
| Biotronik INC. | $41.37 | 2020-2021 | |
| Medicomp INC | $38.80 | 2022 | |
| Alnylam Pharmaceuticals INC. | $35.61 | 2021-2025 | Amvuttra |
| Sanofi-Aventis U.S. LLC | $32.12 | 2019 | |
| Medtronic, INC. | $21.47 | 2024 | Micra |
| Opsens INC. | $16.86 | 2019 | |
| Baxter Healthcare | $16.59 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Kiniksa Pharmaceuticals, LTD. | $12.92 | 2023 | Arcalyst |
| Penumbra, INC. | $1.63 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Waddah Salman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.